SPC
ACTU

Sigma Planning Corp’s Actuate Therapeutics ACTU Stock Holding History

Sigma Planning Corp’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-23,675
Closed -$160K – 1344
2025
Q1 		$160K Buy
23,675
+7,600
+47% +$61K 0.01% 1134
2024
Q4 		$128K Buy
+16,075
New +$131K ﹤0.01% 1118

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NU
Northwestern University Evanston, Illinois $63.3M AUM 0.76% 1-Year Est. Return
GG
Gleason Group Prospect, Kentucky $1.15B AUM 21.11% 1-Year Est. Return

Sigma Planning Corp's ACTU Position: Q2 2025 in Review

Sigma Planning Corp sold out of Actuate Therapeutics (ACTU) in Q2 2025, closing a stake of 23,675 shares — an estimated $160K sold.

Sigma Planning Corp first reported a position in ACTU in Q4 2024 and held it in 2 quarters. The position peaked at $160K in Q1 2025. 38 funds tracked by Wall St. Rank hold ACTU as of Q2 2025.

  • Sigma Planning Corp reported no remaining Actuate Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Sigma Planning Corp sold 23,675 Actuate Therapeutics shares in Q2 2025, an estimated $160K.
  • Sigma Planning Corp first reported a position in Actuate Therapeutics in Q4 2024 and held it in 2 quarters.
  • Sigma Planning Corp's Actuate Therapeutics position peaked at $160K in Q1 2025.
  • 38 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2025.

Based on Sigma Planning Corp's 13F filing for Q2 2025, filed 5 Aug 2025.